Dr. Salini James and Ms. Cindy Bian> attended a conference, “Enhancing Intellectual Property Protection in Greater China: Contemporary Issues and Critical Analysis” on 27th October 2010 in the University of Hong Kong.
我们的过去活动
Recommended Insights
AI, Big Data, and Blockchain - CNIPA seeks public comment on draft patent examination guidelines
2019年11月21日Exciting new changes continue to happen with the Chinese Patent Office (CNIPA). On November 12, 2019, the CNIPA published a new set of amendments to Part II Chapter 9 of the Patent Examination Guidelines (“Draft”) and requested public comment by December 11, 2019. In summary, the new guidelines clarify how emerging technologies involving artificial intelligence, […]
阅读更多 >
China Releases Draft Implementation Guidelines for the Drug Administration Law
2022年6月2日The latest draft implementation guidelines for China’s Drug Administration Law (“Guidelines”) are out and open for comment. Previously, the new implementation measures for early dispute resolution mechanisms for drug patents (“Patent Linkage Measures”) came into effect on July 4, 2021. The Guidelines indicate that the final approval of generic chemical drug applications for marketing approval […]
阅读更多 >
Do Invention and UM Patents Filed on the Same Day Rise and Fall Together?
2021年8月19日Snippets of Court Cases, Provisions, and Key Observations about China’s IP Landscape Seminal Cases by the SPC Recently, the Intellectual Property Division of the Supreme People's Court (SPC) issued a list of seminal (精品) cases. Although China is not a case law country, such seminal cases issued by the SPC have high guiding impact for […]
阅读更多 >
China’s Newest Examination Guidelines: Inventive Step for Biological / Life Science Inventions (Part III)
2021年4月30日This is Part III of a three-part series summarizing the Examination Guidelines that were released by the CNIPA on January 15, 2021, one year to the date of Phase 1 of the US and China Economic and Trade Agreement. That agreement included specific provisions where China "shall permit pharmaceutical patent applicants to rely on supplemental […]
阅读更多 >